Presentation Date/Time: Sunday, December 11 from 6:00 PM - 8:00 PMPoster Title: The HDAC Inhibitor Entinostat (SNDX-275) Induces Clinical Responses in Patients with Relapsed and Refractory Hodgkin's Lymphoma: Results of ENGAGE-501 Multicenter Phase 2 Study Program/Session: Oral and Poster Abstracts, 624. Lymphoma- Therapy with Biologic Agents, excluding Pre-Clinical Models: Poster Abstract Number: 2715Location: Hall GH (San Diego Convention Center)

Presentation Date/Time: Saturday, December 10, 2011: 5:30 PM-7:30 PMPoster Title: HDAC and LSD1 Inhibitors Synergize to Induce Cell Death in Acute Leukemia Cells Program/Session: Oral and Poster Abstracts, 604. Molecular Pharmacology, Drug Resistance: Poster IAbstract Number: 1427Location: Hall GH (San Diego Convention Center)

Presentation Date/Time: Monday, December 12 from 6:00 PM - 8:00 PMPoster Title: Entinostat, a Novel Histone Deacetylase (HiDAC) Inhibitor Enhances the Anti-Tumor Activity of Bortezomib (BTZ) in Rituximab-Chemotherapy Sensitive and Resistant Lymphoma Cell Lines Program/Session: Oral and Poster Abstracts, 625. Lymphoma - Pre-Clinical - Chemotherapy and Biologic Agents: Poster III Abstract Number: 3734Location: Hall GH (San Diego Convention Center)

SOURCE Syndax Pharmaceuticals, Inc.